Andreas Obwaller
Overview
Explore the profile of Andreas Obwaller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drinic M, Raninger A, Zraunig A, Astelbauer F, Leitsch D, Obwaller A, et al.
Int J Parasitol Drugs Drug Resist
. 2019 Sep;
10:109-117.
PMID: 31472356
Entamoeba histolytica and Giardia duodenalis are widespread intestinal protozoan parasites which both spread via cysts that have to be ingested to infect a new host. Their environment, the small intestine...
2.
Schneider R, Obwaller A, Auer H
Parasitol Res
. 2014 Nov;
114(1):305-10.
PMID: 25367210
Visceral larva migrans (VLM) syndrome caused by Toxocara canis larvae was first described in the 1950s. The role of other nematode larvae, i.e. the pig roundworm Ascaris suum as a...
3.
Wachter B, Syrowatka M, Obwaller A, Walochnik J
Wien Klin Wochenschr
. 2014 Mar;
126 Suppl 1:S32-6.
PMID: 24619489
Trichomonosis, the disease caused by the protozoan parasite Trichomonas vaginalis, is the most common curable sexually transmitted disease with 174 million cases per year worldwide. The emerging resistance against the...
4.
Polat Z, Walochnik J, Obwaller A, Vural A, Dursun A, Arici M
Clin Exp Ophthalmol
. 2013 Apr;
42(2):151-8.
PMID: 23601234
Background: In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used...
5.
Astelbauer F, Gruber M, Brem B, Greger H, Obwaller A, Wernsdorfer G, et al.
Acta Trop
. 2012 Apr;
123(2):96-100.
PMID: 22537982
According to the WHO, in 2008, there were 247 million reported cases of malaria and nearly one million deaths from the disease. Parasite resistance against first-line drugs, including artemisinin and...
6.
Akin Polat Z, Obwaller A, Vural A, Walochnik J
Parasitol Res
. 2011 Jul;
110(2):515-20.
PMID: 21748351
Acanthamoeba keratitis is a painful corneal infection and difficult to treat because no sufficiently efficient drug has yet been available. The aim of the study therefore was to assess the...
7.
Astelbauer F, Obwaller A, Raninger A, Brem B, Greger H, Duchene M, et al.
Vector Borne Zoonotic Dis
. 2011 Mar;
11(7):793-8.
PMID: 21417924
Visceral and cutaneous leishmaniases are an important public health problem in endemic geographic regions in 88 countries worldwide, with around 12 million infected people. Treatment options are limited due to...
8.
Astelbauer F, Obwaller A, Raninger A, Brem B, Greger H, Duchene M, et al.
Int J Antimicrob Agents
. 2010 Sep;
36(6):570-2.
PMID: 20851577
Chagas disease, caused by Trypanosoma cruzi, represents an important public health problem in endemic geographic regions in Middle and South America, affecting 15 million infected people. Treatment options are still...
9.
Walochnik J, Obwaller A, Gruber F, Mildner M, Tschachler E, Suchomel M, et al.
J Antimicrob Chemother
. 2009 Jun;
64(3):539-45.
PMID: 19549672
Objectives: Acanthamoebae can cause infections of several organs, including eye, skin, lung and brain. Except for Acanthamoeba keratitis, these infections are linked to immunodeficiency. Treatment is generally problematic, due to...
10.
Balic M, Dandachi N, Hofmann G, Samonigg H, Loibner H, Obwaller A, et al.
Cytometry B Clin Cytom
. 2005 Sep;
68(1):25-30.
PMID: 16142788
Background: Monitoring of circulating tumor cells (CTCs) in blood of carcinoma patients treated with novel compounds may be a measurement of treatment effectiveness. Before it can be used clinically, a...